{"id":683,"date":"2026-05-26T21:57:06","date_gmt":"2026-05-26T21:57:06","guid":{"rendered":"https:\/\/menteymanzana.com\/?p=683"},"modified":"2026-05-26T22:30:42","modified_gmt":"2026-05-26T22:30:42","slug":"vacunas-covid-19-anatomia-forense-farmacovigilancia-litigios-2020-2026","status":"publish","type":"post","link":"https:\/\/menteymanzana.com\/en\/vacunas-covid-19-anatomia-forense-farmacovigilancia-litigios-2020-2026\/","title":{"rendered":"COVID-19 Vaccines: A Six-Year Forensic Anatomy of Pharmacovigilance, Litigation, and Contractual Opacity (2020\u20132026)"},"content":{"rendered":"<style>\n\/* === Ocultar elementos del tema para layout custom (estilo Sildenafilo) === *\/\nbody.postid-683>.wp-site-blocks>main.wp-block-group{display:none!important}\nbody.postid-683 .wp-site-blocks>.wp-block-group.has-global-padding{padding-top:0!important}\nbody.postid-683 .wp-site-blocks>.wp-block-group>.wp-block-group:first-child{padding-top:0!important;margin-top:0!important}\nbody.postid-683 .entry-title{display:none!important}\nbody.postid-683 .wp-block-post-title{display:none!important}\nbody.postid-683 main{padding-top:0!important}\nbody.postid-683 .post-thumbnail,body.postid-683 .wp-block-post-featured-image{display:none!important;margin-top:0!important;margin-bottom:0!important}\nbody.postid-683 article>*:first-child,body.postid-683 .entry-content{margin-top:0!important;padding-top:0!important}\n\n\/* === Titulo custom === *\/\nbody.postid-683 h1.mm-custom-title{color:#fff!important;font-size:2.4em;line-height:1.2;margin:0.6em 0 0.4em;text-align:center;font-weight:800;letter-spacing:-.01em}\nbody.postid-683 h1.mm-custom-title .accent{color:#c6f432}\nbody.postid-683 .mm-subtitle{color:#c6f432;text-align:center;font-size:1.05em;font-weight:600;letter-spacing:.04em;text-transform:uppercase;margin:0 0 1.8em}\n\n\/* === Hero === *\/\nbody.postid-683 .mm-hero{margin:0 0 1.5em!important}\nbody.postid-683 .mm-hero img{width:100%;max-height:480px;object-fit:cover;display:block;border-radius:6px}\n\n\/* === Contenido === *\/\nbody.postid-683 .mm-content h2{color:#c6f432!important;font-size:1.55em;margin:1.8em 0 .7em;clear:both;border-bottom:2px solid rgba(198,244,50,.25);padding-bottom:.35em}\nbody.postid-683 .mm-content h3{color:#fff!important;font-size:1.2em;margin:1.2em 0 .55em;clear:both;width:100%}\nbody.postid-683 .mm-content p{color:#e8e8e8;line-height:1.7;margin:0 0 1em;font-size:1rem}\nbody.postid-683 .mm-content strong{color:#fff}\nbody.postid-683 .mm-content em{color:#cccccc}\nbody.postid-683 .mm-content ul{color:#e8e8e8;margin:.8rem 0 1.2rem 1.25rem;line-height:1.7}\nbody.postid-683 .mm-content ul li{margin-bottom:.4rem}\n\n\/* === Imagenes de seccion === *\/\nbody.postid-683 .mm-content figure.mm-section-img{margin:1.4em 0 1.6em;border-radius:6px;overflow:hidden;border:1px solid rgba(198,244,50,.18);box-shadow:0 6px 18px rgba(0,0,0,.35)}\nbody.postid-683 .mm-content figure.mm-section-img img{width:100%;height:auto;display:block}\nbody.postid-683 .mm-content figure.mm-section-img figcaption{background:#1a1a1a;color:#c6f432;padding:.6rem .9rem;font-size:.85rem;font-style:italic;text-align:center;border-top:1px solid rgba(198,244,50,.2)}\n\n\/* === Callout === *\/\nbody.postid-683 .mm-callout{background:rgba(198,244,50,.06);border-left:3px solid #c6f432;border-radius:4px;padding:1em 1.25em;margin:1.5em 0;color:#e8e8e8}\nbody.postid-683 .mm-callout strong{color:#c6f432}\n\n\/* === Disclaimer === *\/\nbody.postid-683 .mm-disclaimer{background:rgba(244,211,94,.06);border:1px solid rgba(244,211,94,.3);border-radius:6px;padding:1em 1.25em;margin:1.2em 0 1.6em;color:#f4d35e;font-size:.93em}\nbody.postid-683 .mm-disclaimer strong{color:#ffe680}\n\n\/* === Blockquote === *\/\nbody.postid-683 .mm-content blockquote{background:#1a1a1a;color:#fff;padding:1.1rem 1.5rem;border-radius:6px;margin:1.4rem 0;font-size:1.05rem;border-left:4px solid #c6f432}\nbody.postid-683 .mm-content blockquote .mm-source{display:block;margin-top:.6rem;font-size:.83rem;color:#c6f432;font-weight:600}\n\n\/* === Tablas === *\/\nbody.postid-683 .mm-content table{width:100%;border-collapse:collapse;margin:1.2rem 0;font-size:.88rem;background:#161616;border-radius:6px;overflow:hidden;box-shadow:0 4px 12px rgba(0,0,0,.3)}\nbody.postid-683 .mm-content table th{background:#c6f432;color:#0a0a0a;padding:.65rem .8rem;text-align:left;font-weight:800;font-size:.82rem;text-transform:uppercase;letter-spacing:.03em}\nbody.postid-683 .mm-content table td{padding:.6rem .8rem;border-bottom:1px solid rgba(255,255,255,.08);vertical-align:top;color:#d8d8d8}\nbody.postid-683 .mm-content table tr:nth-child(even) td{background:rgba(255,255,255,.025)}\nbody.postid-683 .mm-content table strong{color:#c6f432}\n\n\/* === Keyfig === *\/\nbody.postid-683 .mm-keyfig{display:inline-block;background:#c6f432;color:#0a0a0a;font-weight:800;padding:.1rem .5rem;border-radius:3px;font-size:.92em;white-space:nowrap}\n\n\/* === Referencias === *\/\nbody.postid-683 .mm-refs{margin-top:2em;padding:1.3em 1.6em;background:rgba(198,244,50,.05);border-left:3px solid #c6f432;border-radius:4px}\nbody.postid-683 .mm-refs h3{color:#c6f432!important;margin-top:0;font-size:1.1rem}\nbody.postid-683 .mm-refs ol{padding-left:1.3rem;margin:.5em 0 0;color:#cfcfcf}\nbody.postid-683 .mm-refs li{margin-bottom:.5em;font-size:.9em;line-height:1.55}\nbody.postid-683 .mm-refs em{color:#cccccc}\n\n\/* === Mobile === *\/\n@media(max-width:680px){\n  body.postid-683 h1.mm-custom-title{font-size:1.55em}\n  body.postid-683 .mm-subtitle{font-size:.9em}\n  body.postid-683 .mm-content h2{font-size:1.3em}\n  body.postid-683 .mm-content h3{font-size:1.1em}\n  body.postid-683 .mm-content p{font-size:.95rem}\n  body.postid-683 .mm-content table{font-size:.78rem}\n  body.postid-683 .mm-content table th,body.postid-683 .mm-content table td{padding:.45rem .55rem}\n}\n<\/style>\n\n<div class=\"mm-hero\"><img decoding=\"async\" src=\"https:\/\/menteymanzana.com\/wp-content\/uploads\/2026\/05\/vacunas-01-hero.png\" alt=\"Balanza forense entre un vial de vacuna y documentos legales sellados\" \/><\/div>\n\n<h1 class=\"mm-custom-title\">VACCINES <span class=\"accent\">COVID-19<\/span>: ANATOMY <span class=\"accent\">FORENSIC<\/span><\/h1>\n<p class=\"mm-subtitle\">Six Years of Pharmacovigilance, Litigation and Contractual Opacity (2020\u20132026)<\/p>\n\n<div class=\"mm-content\">\n\n<div class=\"mm-disclaimer\"><strong>Editorial note.<\/strong> This dossier is a review of post-marketing pharmacovigilance and regulatory law. <strong>It does not constitute an anti-vaccine position.<\/strong> The overall risk-benefit balance of immunization against SARS-CoV-2 remains favorable for most cohorts according to the cited agencies themselves (EMA, FDA, CDC, WHO).<\/div>\n\n<p>The SARS-CoV-2 pandemic precipitated an unprecedented scientific, financial, and regulatory effort that culminated in the global deployment of vaccines based on innovative platforms\u2014messenger RNA and adenoviral vectors\u2014and traditional technologies. The shortening of clinical development timelines through mechanisms such as <em>Operation Warp Speed<\/em> in the United States and accelerated assessments (<em>rolling reviews<\/em>) from the European Medicines Agency (EMA) made it possible to decisively mitigate global morbidity and mortality.<\/p>\n\n<p>However, the mass administration to billions of subjects exposed the inherent limitations of pharmacovigilance in phase III clinical trials, revealing rare but clinically significant safety signals that altered public health strategies. This report summarizes, from an epidemiological and international pharmaceutical law perspective, the regulatory restrictions, validated adverse effects, resulting litigation, and contractual disputes that have marked the evolution of this phenomenon between 2020 and May 2026.<\/p>\n\n<div class=\"mm-callout\"><strong>The essentials in three lines.<\/strong> Adenoviral vaccines (AstraZeneca, Janssen) were withdrawn or restricted after confirming the VITT\/TTS thrombotic syndrome. mRNA vaccines (Pfizer, Moderna) showed a risk of myocarditis concentrated in young men. State compensation systems approved a minimal fraction of claims (~0.31 TP3T in the US), while European and US courts ordered forced transparency regarding contracts and clinical data.<\/div>\n\n<h2>Module 1 \u2014 The Silent Withdrawal<\/h2>\n\n<figure class=\"mm-section-img\"><img decoding=\"async\" src=\"https:\/\/menteymanzana.com\/wp-content\/uploads\/2026\/05\/vacunas-02-modulo1-retirada.png\" alt=\"Vial de vacuna con sello de retirada sobre superficie de laboratorio\" \/><figcaption>Post-marketing pharmacovigilance corrected decisions made under pandemic pressure.<\/figcaption><\/figure>\n\n<h3>AstraZeneca case (Vaxzevria): From European suspension to global withdrawal<\/h3>\n\n<p>The ChAdOx1-S (recombinant) vaccine, marketed as <strong>Vaxzevria<\/strong> y <strong>Covidhield<\/strong>, It constituted one of the initial pillars of global immunization, demonstrating the efficacy of 100% against severe disease in clinical trials. In mid-March 2021, a critical accumulation of spontaneous reports of atypical thromboembolic events forced drastic regulatory intervention in Europe.<\/p>\n\n<p>Denmark, Norway, and Germany were pioneers in discontinuing the procedure after identifying unusual patterns of cerebral blood clots combined with abnormally low platelet levels. Danish-Norwegian cohort studies (n=281,264 recipients) reported concerning standardized incidence rates of venous thromboembolism. <span class=\"mm-keyfig\">1.97 (CI 95%: 1.50\u20132.54)<\/span> and thrombocytopenia <span class=\"mm-keyfig\">3.02 (CI 95%: 1.76\u20134.83)<\/span> within 28 days of vaccination.<\/p>\n\n<p>On March 18, 2021, the EMA and its Pharmacovigilance Risk Assessment Committee (PRAC) formally intervened, recognizing these events as side effects in April 2021. <em>\u00ab&quot;very strange&quot;\u00bb<\/em> but biologically plausible. Most European countries implemented strict age restrictions, limiting Vaxzevria to populations over 60 years of age.<\/p>\n\n<p>The product life cycle culminated on <strong>March 27, 2024<\/strong>, When the European Commission, at the request of the marketing authorization holder (AstraZeneca AB), permanently revoked the authorization in the EU. Weeks later, on April 23, 2024, the <em>Therapeutic Goods Administration<\/em> The Australian TGA cancelled the registration. The corporation justified the withdrawal on the grounds that... <em>\u00ab&quot;surplus of newer vaccines&quot;\u00bb<\/em> and a drop in sales <span class=\"mm-keyfig\">from USD 4,000 M (2021) to USD 12 M (2023)<\/span>.<\/p>\n\n<h3>Janssen Case (Johnson &amp; Johnson): Cancellation of Emergency Use in the U.S.<\/h3>\n\n<p>The adenoviral vector vaccine Ad26.COV2.S experienced a similar trajectory. In April 2021, the FDA and CDC issued an immediate clinical pause after confirming six severe cases of cerebral venous sinus thrombosis with thrombocytopenia among more than 6.8 million doses administered.<\/p>\n\n<p>Although the pause was lifted on April 23, 2021, the VAERS and v-safe systems documented a worsening situation. By March 2022, the analysis revealed a reporting rate of <span class=\"mm-keyfig\">3.23 cases of TTS and 0.48 deaths per million doses<\/span>, ...disproportionately affecting women aged 30 to 49. In December 2021, the ACIP issued a preferential recommendation in favor of mRNA vaccines over Janssen.<\/p>\n\n<p>Finally, citing the expiration of the last federal lots and the company&#039;s refusal to update the composition for emerging variants, the FDA definitively revoked EUA 27205 on <strong>June 1, 2023<\/strong>, under the signature of Dr. Peter Marks, Director of CBER.<\/p>\n\n<h3>Nordic restrictions on mRNA vaccines<\/h3>\n\n<p>While mRNA platforms demonstrated a superior profile compared to adenoviral vectors in terms of thrombotic events, prospective surveillance identified a disproportionate risk of cardiac inflammation. In early October 2021, the public health agencies of Sweden, Denmark, Finland, and Norway <strong>Spikevax (Moderna) was suspended or discouraged in men under 30 years of age.<\/strong>, transitioning to Comirnaty (Pfizer) as the exclusive vaccine in that cohort.<\/p>\n\n<h2>Module 2 \u2014 Litigation and Transparency<\/h2>\n\n<figure class=\"mm-section-img\"><img decoding=\"async\" src=\"https:\/\/menteymanzana.com\/wp-content\/uploads\/2026\/05\/vacunas-03-modulo2-litigios.png\" alt=\"Mazo judicial sobre dossier legal en biblioteca cl\u00e1sica\" \/><figcaption>Judicial action has been the corrective mechanism when regulatory transparency has failed.<\/figcaption><\/figure>\n\n<h3>Civil lawsuits in the United Kingdom (London High Court)<\/h3>\n\n<p>AstraZeneca faces consolidated civil claims in the High Court of London under the <em>Consumer Protection Law<\/em>. Flagship cases include Jamie Scott \u2014diagnosed with vaccine-induced immune thrombocytopenia (VITT) after his immunization in April 2021 and with permanent brain damage\u2014 and Anish Tailor, whose wife Alpa Tailor died from VITT-induced blood clots and brain hemorrhage.<\/p>\n\n<p>Represented by specialized law firms such as <strong>Hausfeld<\/strong> y <strong>Leigh Day<\/strong>, Dozens of litigants argue that the biological product was legally <em>\u00ab&quot;defective&quot;\u00bb<\/em> in its risk-benefit analysis. The corporate defense maintains that patient safety was always the priority.<\/p>\n\n<h3>The systemic failure of state compensation programs<\/h3>\n\n<p>The near-absolute legal immunity clauses granted to manufacturers forced victims to resort to compensation schemes. <em>no-fault<\/em>. Comprehensive analyses reveal systemic deficiencies:<\/p>\n\n<table><thead><tr><th>Country<\/th><th>System<\/th><th>Claims<\/th><th>Approved<\/th><th>Rate<\/th><\/tr><\/thead><tbody><tr><td>USA.<\/td><td>CICP (HRSA)<\/td><td>14 135<\/td><td>102 eligible \/ 56 compensated<\/td><td><strong>~0.3%<\/strong><\/td><\/tr><tr><td>United Kingdom<\/td><td>VDPS<\/td><td>&gt; 22,294<\/td><td>~240<\/td><td><strong>~1.1%<\/strong><\/td><\/tr><tr><td>Japan<\/td><td>Health Damage Relief<\/td><td>14 933<\/td><td>9 454<\/td><td><strong>~63.3%<\/strong><\/td><\/tr><tr><td>Germany<\/td><td>Federal system<\/td><td>Not centralized<\/td><td>Accessible<\/td><td>\u2014<\/td><\/tr><\/tbody><\/table>\n\n<p>The HRSA database (May 2026) reveals the magnitude of US administrative denials: 7,066 rejected claims. The reasons are procedural: <strong>2 768<\/strong> due to lack of medical records, <strong>2 619<\/strong> for failing to meet the 1-year filing deadline. TTS\/VITT cases have generated the largest payouts, notably one claim compensated with <span class=\"mm-keyfig\">USD 5,942,538.84<\/span>.<\/p>\n\n<h3>The European dispute: &quot;Pfizergate&quot; and case T-36\/23 before the CJEU<\/h3>\n\n<p>At the level of supranational administrative law, the most disruptive litigation was the case <em>Stevi and The New York Times v Commission<\/em> (T-36\/23) before the Grand Chamber of the General Court of the CJEU. The dispute arose from the framework agreement for the acquisition of <strong>1.8 billion doses<\/strong> of mRNA vaccines for approximately \u20ac15.5 per dose (~\u20ac35 billion), negotiated directly via SMS and telephone calls between Ursula von der Leyen and Albert Bourla.<\/p>\n\n<p>He <strong>May 14, 2025<\/strong>, The General Court ruled unequivocally in favor of the NYT, overturning the Commission&#039;s decision. The ruling dismantled the <em>\u00ab&quot;evasive justifications&quot;\u00bb<\/em> and established axiomatically that informal communications that determine sovereign decisions are subject to legal scrutiny.<\/p>\n\n<h3>Forced release of Pfizer data (USA, Case 4:21cv01058)<\/h3>\n\n<p>The organization <em>Public Health and Medical Professionals for Transparency<\/em> (PHMPT) sued the FDA under the Freedom of Information Act (FOIA). In its defense, the FDA proposed releasing 500 pages per month\u2014a timeline that would have delayed full disclosure until next year. <strong>2097<\/strong>.<\/p>\n\n<blockquote>\u00ab&quot;Excessive delay fuels conspiracy theories and undermines public trust in government evaluation.&quot;\u00bb<span class=\"mm-source\">\u2014 Judge Mark Pittman, Northern District of Texas, acceleration order to 55,000 pages per month.<\/span><\/blockquote>\n\n<h2>Module 3 \u2014 Confirmed Syndromes<\/h2>\n\n<figure class=\"mm-section-img\"><img decoding=\"async\" src=\"https:\/\/menteymanzana.com\/wp-content\/uploads\/2026\/05\/vacunas-04-modulo3-sindromes.png\" alt=\"Visualizaci\u00f3n microsc\u00f3pica de plaquetas y anticuerpos en cascada inmune\" \/><figcaption>Platelet factor 4 (PF4) is the pathological axis of VITT\/TTS syndrome.<\/figcaption><\/figure>\n\n<h3>VITT\/TTS: Adenoviral vector-induced immune thrombosis<\/h3>\n\n<p>He <strong>Vaccine-Induced Immune Thrombocytopenia Syndrome (VITT\/TTS)<\/strong> It is a severe immunological phenotype inextricably linked to non-replicating adenoviral vector platforms (AstraZeneca&#039;s ChAdOx1-S and Janssen&#039;s Ad26.COV2.S). Pathophysiologically, the syndrome is triggered by the formation of abnormal IgG antibodies against the virus. <strong>platelet factor 4 (PF4)<\/strong>.<\/p>\n\n<p>The clinical picture manifests between days 4 and 30 post-vaccination, characterized by arterial or venous thrombosis in unusual locations\u2014predominantly cerebral venous sinus (CVST) thrombosis and splanchnic thrombosis. The early incidence was <span class=\"mm-keyfig\">~1 case per 150,000 vaccinated<\/span>. The initial mortality rate was around 50%, later reduced to 5\u201322% thanks to WHO guidelines that contraindicate heparin and promote intravenous immunoglobulin.<\/p>\n\n<h3>Post-mRNA myocarditis: the risk concentrated in young men<\/h3>\n\n<p>Acute myocardial inflammation was formally included as a warning in the package inserts for Comirnaty (Pfizer) and Spikevax (Moderna) by the FDA and EMA. The statistical signal is highly concentrated in adolescent and young adult males (12\u201329 years), appearing within the first 7 days after the second dose.<\/p>\n\n<p>Analysis of the <em>American Heart Association<\/em> Over 43 million people demonstrate:<\/p>\n\n<table><thead><tr><th>Cohort<\/th><th>Vaccine risk<\/th><th>Risk of infection<\/th><th>Verdict<\/th><\/tr><\/thead><tbody><tr><td>General population<\/td><td>Transient increase post-2nd dose<\/td><td><strong>11x larger<\/strong> post-infection<\/td><td>Net benefit in favor of vaccination<\/td><\/tr><tr><td>Men &gt; 40 years<\/td><td>Tiniest<\/td><td>85 additional cases\/million<\/td><td>Universal recommendation<\/td><\/tr><tr><td>Males &lt; 40 years<\/td><td>~6\/100,000 secondary doses<\/td><td>16 additional cases\/million<\/td><td><strong>Critical intersection<\/strong> with 2nd dose Spikevax<\/td><\/tr><\/tbody><\/table>\n\n<h3>Guillain-Barr\u00e9: a specific Janssen sign<\/h3>\n\n<p>Guillain-Barr\u00e9 syndrome (GBS) was causally associated with Ad26.COV2.S. <em>Vaccine Safety Datalink<\/em> documented an unadjusted incidence of <span class=\"mm-keyfig\">32.4 cases\/100,000 person-year<\/span> In the 21 days following Janssen, the incidence was dramatically higher than the baseline incidence of 1\u20132\/100,000. The incidence after mRNA vaccines (1.3\/100,000) was not statistically significant.<\/p>\n\n<h3>Heavy menstrual bleeding: a signal initially silenced<\/h3>\n\n<p>Initial alerts were downplayed, but the prospective workload (&gt;34,000 reports to EudraVigilance) necessitated a formal review. <strong>October 2022<\/strong>, EMA&#039;s PRAC ruled to add the <em>\u00ab&quot;heavy menstrual bleeding&quot;\u00bb<\/em> as an adverse effect with <em>\u00ab&quot;reasonable possibility of causal association&quot;\u00bb<\/em>.<\/p>\n\n<p>Norwegian studies (Trogstad et al.) established a Relative Risk of <span class=\"mm-keyfig\">RR 1.90 (1st dose)<\/span> y <span class=\"mm-keyfig\">RR 1.84 (2nd dose)<\/span>. Clinically, the abnormalities are transient (&lt; 8 days of variation) and show no impact on fertility rates.<\/p>\n\n<h2>Module 4 \u2014 Ventavia, Indemnity and Sovereign Immunity<\/h2>\n\n<figure class=\"mm-section-img\"><img decoding=\"async\" src=\"https:\/\/menteymanzana.com\/wp-content\/uploads\/2026\/05\/vacunas-05-modulo4-indemnidad.png\" alt=\"Contrato con cl\u00e1usulas redactadas en negro y bandera latinoamericana al fondo\" \/><figcaption>Contractual indemnity was the price imposed on sovereign states desperate for healthcare.<\/figcaption><\/figure>\n\n<h3>The Ventavia case: Brook Jackson&#039;s complaint in the BMJ<\/h3>\n\n<p>In November 2021, <em>The BMJ<\/em> He published a devastating investigation by journalist Paul Thacker based on the revelations of <strong>Brook Jackson<\/strong>, regional director of Ventavia Research Group\u2014a CRO subcontracted by Pfizer to operate Phase III trial sites in Texas. Audited internal documents revealed systemic failures: breaches of double-blinding, data falsification, medical staff without certified training, negligent cold storage, and delays in following up on adverse events.<\/p>\n\n<p>Jackson filed a lawsuit <em>qui tam<\/em> under the False Claims Act (Civil Action) <strong>1:21-CV-00008-MJT<\/strong>On March 31, 2023, Judge Michael J. Truncale ruled in favor of the pharmaceutical companies. The court <strong>He did not provide evidence to refute the anomalies<\/strong>, but ruled under the standard of <em>\u00ab&quot;Materiality&quot;\u00bb<\/em>The government\u2014notified of the failures in September 2020\u2014proceeded with the authorizations and disbursements anyway.<\/p>\n\n<h3>Sovereign indemnity: the price for Latin America<\/h3>\n\n<p>Investigations of <em>The Bureau of Investigative Journalism<\/em> They revealed that Pfizer imposed exceptional liability exemption demands on Latin American republics. In Brazil and Argentina, deliveries of biologics were conditioned on the states:<\/p>\n\n<ul><li>They would grant indefinite civil amnesty for any side effects.<\/li><li>They were erected as <strong>financial guarantors of the laboratory<\/strong>.<\/li><li>They will lift sovereign immunity on state assets.<\/li><li>They registered <strong>central bank reserves, military bases and offshore deposits<\/strong> as attachable guarantee funds.<\/li><\/ul>\n\n<p>According to leaked drafts, Pfizer intended to guarantee indemnity even in scenarios where injuries were caused by malpractice, negligence, malice, or fraud on the part of the company itself. The final Brazilian contract obligated the nation to submit to the jurisdiction of courts in New York, mandating legally secret arbitration.<\/p>\n\n<blockquote>Monopolistic corporations used control of essential medical technology as a tool to erode constitutional dogmas of public administrative law.<span class=\"mm-source\">\u2014 Synthesis of academic analyses of global health and international law.<\/span><\/blockquote>\n\n<h2>Forensic Balance: What Six Years Taught Us<\/h2>\n\n<p>The clinical-legal record of the vaccine response to the pandemic leaves four unequivocal lessons for epidemiology and pharmaceutical law in the 21st century:<\/p>\n\n<p><strong>First<\/strong>, The compressed timelines of clinical development necessarily shift some of the detection of rare signals to the post-marketing stage. VITT\/TTS, mRNA myocarditis, and post-Janssen GBS are evidence that active pharmacovigilance worked: agencies detected, validated, and intervened within months.<\/p>\n\n<p><strong>Second<\/strong>, the aggregate risk-benefit balance <strong>remains favorable<\/strong> for most cohorts. The documented exception\u2014the second dose of Spikevax in men &lt; 30 years\u2014justified surgical interventions, not mass withdrawal.<\/p>\n\n<p><strong>Third<\/strong>, the compensation systems <em>no-fault<\/em> They have failed systemically in the US and UK (approved at ~0.3% and ~1.1%, respectively), while Japan has demonstrated that an inclusive approach allows for fiscally sustainable rates of 63%. The asymmetry is political, not actuarial.<\/p>\n\n<p><strong>Room<\/strong>, contractual opacity <strong>It is indefensible.<\/strong> in a liberal democracy. The precedent of the CJEU (T-36\/23) and the Pittman order in Texas establish cross-cutting jurisprudence: informal communications that compromise sovereign decisions and clinical data that support authorizations are subject to legal scrutiny.<\/p>\n\n<p>The question is no longer whether the pandemic response was scientifically justifiable\u2014it was. The question is whether the governance mechanisms, contract transparency, and compensation for victims are adequate for the next health emergency. As of May 2026, the documented response suggests that <strong>They are not<\/strong>.<\/p>\n\n<div class=\"mm-refs\"><h3>Selected references<\/h3><ol><li>EMA (2024, March 27). <em>Public Statement: Withdrawal of marketing authorization for Vaxzevria.<\/em> EMEA\/H\/C\/005675.<\/li><li>TGA Australia (April 23, 2024). <em>Regulatory decision notice: COVID-19 Vaccine AstraZeneca Vaxzevria.<\/em><\/li><li>CDC\/ACIP (2021, December 16). <em>MMWR Morb Mortal Wkly Rep, 71.<\/em><\/li><li>FDA \/ Dr. Peter Marks (2023, June 1). <em>Revocation of Emergency Use of a Biological Product: Janssen COVID-19 Vaccine.<\/em> USA 27205.<\/li><li>Potteg\u00e5rd A. et al. (2021). BMJ, 373:n1114.<\/li><li>General Court of the EU (2025). <em>Stevi and The New York Times v European Commission.<\/em> Case T-36\/23.<\/li><li>US District Court, Northern District of Texas (2022). <em>PHMPT v. FDA.<\/em> Judge Mark Pittman.<\/li><li>HRSA (May 2026). <em>Countermeasures Injury Compensation Program (CICP) Data.<\/em><\/li><li>Thacker PD (2021). <em>Covid-19: Researcher blows the whistle on data integrity issues in Pfizer&#039;s vaccine trial.<\/em> BMJ, 375:n2635.<\/li><li>US District Court, Eastern District of Texas (2023). <em>US ex rel. Brook Jackson v. Ventavia Research Group.<\/em> Civil Action 1:21-CV-00008-MJT.<\/li><li>American Heart Association\/Circulation (2022). <em>Myocarditis With COVID-19 mRNA Vaccines.<\/em><\/li><li>Trogstad L. et al. (2023). EMA-PRAC October 2022.<\/li><li>The Bureau of Investigative Journalism \/ The Guardian (2021).<\/li><li>Sydow C. (2023). NYU Journal of International Law and Politics, Vol. 55:129.<\/li><\/ol><\/div>\n\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Six years of clinical evidence, court rulings, and opaque contracts. A technical dossier on AstraZeneca, Janssen, mRNA, the Pfizergate case before the CJEU, the Ventavia complaint, and the sovereign immunity imposed in Latin America. A review focused exclusively on pharmacovigilance and regulatory law.<\/p>","protected":false},"author":1,"featured_media":686,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[51,45],"tags":[],"class_list":["post-683","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-longevidad-metricas","category-noticias"],"acf":{"hallazgo_clave":"Tres s\u00edndromes raros confirmados (VITT, miocarditis ARNm, Guillain-Barr\u00e9 post-Janssen) y opacidad contractual a\u00fan sin resolver.","tiempo_lectura":12,"nivel_evidencia":"alto","fuente_original":"https:\/\/www.bmj.com\/content\/375\/bmj.n2635","protocolo_aplicable":true,"referencias_texto":"","tags_cientificos":"farmacovigilancia, VITT, TTS, miocarditis, ARNm, AstraZeneca, Janssen, Pfizer, Moderna, EMA, FDA, CDC, Pfizergate, TJUE, Ventavia, indemnidad soberana, Brook Jackson, derecho farmac\u00e9utico, OCS, OCDE, HRSA, VAERS"},"hallazgo_clave":"Tres s\u00edndromes raros confirmados (VITT, miocarditis ARNm, Guillain-Barr\u00e9 post-Janssen) y opacidad contractual a\u00fan sin resolver.","tiempo_lectura":"12","nivel_evidencia":"alto","fuente_original":"https:\/\/www.bmj.com\/content\/375\/bmj.n2635","protocolo_aplicable":true,"referencias_texto":"","tags_cientificos":"farmacovigilancia, VITT, TTS, miocarditis, ARNm, AstraZeneca, Janssen, Pfizer, Moderna, EMA, FDA, CDC, Pfizergate, TJUE, Ventavia, indemnidad soberana, Brook Jackson, derecho farmac\u00e9utico, OCS, OCDE, HRSA, VAERS","_links":{"self":[{"href":"https:\/\/menteymanzana.com\/en\/wp-json\/wp\/v2\/posts\/683","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/menteymanzana.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/menteymanzana.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/menteymanzana.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/menteymanzana.com\/en\/wp-json\/wp\/v2\/comments?post=683"}],"version-history":[{"count":5,"href":"https:\/\/menteymanzana.com\/en\/wp-json\/wp\/v2\/posts\/683\/revisions"}],"predecessor-version":[{"id":693,"href":"https:\/\/menteymanzana.com\/en\/wp-json\/wp\/v2\/posts\/683\/revisions\/693"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/menteymanzana.com\/en\/wp-json\/wp\/v2\/media\/686"}],"wp:attachment":[{"href":"https:\/\/menteymanzana.com\/en\/wp-json\/wp\/v2\/media?parent=683"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/menteymanzana.com\/en\/wp-json\/wp\/v2\/categories?post=683"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/menteymanzana.com\/en\/wp-json\/wp\/v2\/tags?post=683"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}